Jesridonin in combination with paclitaxel demonstrates synergistic anti-tumor activity in human esophageal carcinoma cells
| Autor: | Yu Ke, Liping Jiang, Liming Chang, Jun-Wei Wang, Hong-Min Liu, Dongxiao Yang, Kairui Zhou, Sai-Qi Wang, Cong Wang, Ying Liu, Xiaoli Shi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Esophageal Neoplasms Paclitaxel Clinical Biochemistry Pharmaceutical Science Apoptosis Pharmacology Biochemistry 03 medical and health sciences chemistry.chemical_compound Esophagus 0302 clinical medicine In vivo Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols Drug Discovery Carcinoma medicine Humans Cytotoxic T cell Cytotoxicity Molecular Biology Chemistry Organic Chemistry Drug Synergism medicine.disease Antineoplastic Agents Phytogenic In vitro Blot 030104 developmental biology 030220 oncology & carcinogenesis Molecular Medicine Diterpenes Kaurane |
| Zdroj: | Bioorganic & Medicinal Chemistry Letters. 27:2058-2062 |
| ISSN: | 0960-894X |
| DOI: | 10.1016/j.bmcl.2017.02.008 |
| Popis: | The novel compound jesridonin, has extensive anti-tumor activity. In this study, we aim to investigate the cytotoxic effects of jesridonin in combination with paclitaxel. Our results showed that jesridonin in combination with paclitaxel had synergistic cytotoxic effects on human esophageal carcinoma both in vitro and in vivo. Hoechst 33258 staining and the Annexin-V FITC assay demonstrated that paclitaxel synergized with jesridonin in a stronger induction of apoptosis than treatment with paclitaxel or jesridonin alone. Western blotting results revealed that the synergistic apoptosis-induction effects of paclitaxel and jesridonin were mediated by the mitochondrial pathway. This may provide a novel strategy to overcome drug resistance for esophageal cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect